| CSF and blood biomarkers for Parkinson's disease L Parnetti, L Gaetani, P Eusebi, S Paciotti, O Hansson, O El-Agnaf, ... The Lancet Neurology 18 (6), 573-586, 2019 | 464 | 2019 |
| Diagnostic accuracy measures P Eusebi Cerebrovascular Diseases 36 (4), 267-272, 2013 | 341 | 2013 |
| Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease L Parnetti, D Chiasserini, E Persichetti, P Eusebi, S Varghese, ... Movement Disorders 29 (8), 1019-1027, 2014 | 256 | 2014 |
| Cerebrospinal fluid Aβ 42/40 corresponds better than Aβ 42 to amyloid PET in Alzheimer’s disease P Lewczuk, A Matzen, K Blennow, L Parnetti, JL Molinuevo, P Eusebi, ... Journal of Alzheimer's Disease 55 (2), 813-822, 2017 | 245 | 2017 |
| Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: a systematic review and meta‐analysis P Eusebi, D Giannandrea, L Biscetti, I Abraha, D Chiasserini, M Orso, ... Movement disorders 32 (10), 1389-1400, 2017 | 199 | 2017 |
| Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias L Parnetti, D Chiasserini, G Bellomo, D Giannandrea, C De Carlo, ... Movement Disorders 26 (8), 1428-1435, 2011 | 197 | 2011 |
| Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease L Parnetti, L Farotti, P Eusebi, D Chiasserini, C De Carlo, D Giannandrea, ... Frontiers in aging neuroscience 6, 53, 2014 | 186 | 2014 |
| Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies D Chiasserini, S Paciotti, P Eusebi, E Persichetti, A Tasegian, ... Molecular neurodegeneration 10, 1-6, 2015 | 164 | 2015 |
| Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study I Abraha, A Cherubini, F Cozzolino, R De Florio, ML Luchetta, JM Rimland, ... bmj 350, 2015 | 160 | 2015 |
| Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home F Landi, G Dell'Aquila, A Collamati, AM Martone, G Zuliani, B Gasperini, ... Journal of the American Medical Directors Association 15 (11), 825-829, 2014 | 143 | 2014 |
| Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis L Parnetti, E Chipi, N Salvadori, K D’Andrea, P Eusebi Alzheimer's research & therapy 11, 1-13, 2019 | 140 | 2019 |
| A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation L Gaetani, K Höglund, L Parnetti, F Pujol-Calderon, B Becker, P Eusebi, ... Alzheimer's research & therapy 10, 1-13, 2018 | 137 | 2018 |
| Performance of Aβ 1-40, Aβ 1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment L Parnetti, D Chiasserini, P Eusebi, D Giannandrea, G Bellomo, ... Journal of Alzheimer's Disease 29 (1), 229-238, 2012 | 134 | 2012 |
| Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in Parkinson's disease patients L Parnetti, S Paciotti, P Eusebi, A Dardis, S Zampieri, D Chiasserini, ... Movement Disorders 32 (10), 1423-1431, 2017 | 132 | 2017 |
| FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort SP Caminiti, T Ballarini, A Sala, C Cerami, L Presotto, R Santangelo, ... NeuroImage: Clinical 18, 167-177, 2018 | 131 | 2018 |
| Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies TE Moors, S Paciotti, A Ingrassia, M Quadri, G Breedveld, A Tasegian, ... Molecular neurobiology 56, 1344-1355, 2019 | 121 | 2019 |
| Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression NK Majbour, NN Vaikath, P Eusebi, D Chiasserini, M Ardah, S Varghese, ... Movement Disorders 31 (10), 1535-1542, 2016 | 115 | 2016 |
| Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease KD van Dijk, E Persichetti, D Chiasserini, P Eusebi, T Beccari, P Calabresi, ... Movement Disorders 28 (6), 747-754, 2013 | 107 | 2013 |
| Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia D Chiasserini, L Biscetti, P Eusebi, N Salvadori, G Frattini, S Simoni, ... Alzheimer's research & therapy 9, 1-12, 2017 | 104 | 2017 |
| Predictors of hospitalization in Italian nursing home residents: the ULISSE project A Cherubini, P Eusebi, G Dell’Aquila, F Landi, B Gasperini, R Bacuccoli, ... Journal of the American Medical Directors Association 13 (1), 84. e5-84. e10, 2012 | 90 | 2012 |
